Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-04-28 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, the number of shares released from pledge, the proportion of shares involved, and related dates. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, specifically about changes in significant share ownership levels or share pledges. Therefore, the appropriate classification is MRQ (Major Shareholding Notification). The document length is short and focused on shareholding changes, not a report or announcement of a report publication.
2025-04-28 Chinese
关于获得创新药HSK21542注射液新适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration for a new indication clinical trial application of an innovative drug. It details the drug, its intended new use, regulatory acceptance, and risk warnings. The document is short (1395 characters) and serves as an official announcement of regulatory progress rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-27 Chinese
关于2024年度股东大会增加临时提案暨补充通知的公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the 2024 Annual General Meeting (AGM) of 海思科医药集团股份有限公司. It includes information about the meeting date, voting procedures, agenda items including financial reports, board reports, profit distribution, remuneration plans, and proposals for share issuance. It also contains instructions for shareholder registration and proxy voting. The document is not the actual annual report or financial statements but rather a notice and supplementary information about the AGM and its agenda items. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and agenda details. The document length and detail confirm it is not a brief announcement but a full AGM notice with supplementary information.
2025-04-24 Chinese
内幕信息知情人管理制度
Regulatory Filings Classification · 95% confidence The document is a detailed internal management system for insiders' information at a pharmaceutical company, focusing on the management, confidentiality, and registration of insider information and insider personnel. It includes regulatory references, definitions, responsibilities, and procedural requirements related to insider information management. There are no financial statements, earnings data, or investor presentations. It is not an announcement or a brief notice but a comprehensive internal policy document. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and governance-related filing that does not fall into other specific categories like Annual Report, Earnings Release, or Governance Information. The document is over 5,000 characters and contains substantive regulatory and procedural content, not just an announcement or certification.
2025-04-24 Chinese
会计政策、会计估计变更及会计差错管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document from 海思科医药集团股份有限公司 (Hisun Pharmaceutical Group Co., Ltd.) regarding accounting policies, accounting estimate changes, and accounting error management. It outlines procedures, decision-making processes, disclosure requirements, and regulatory compliance related to changes in accounting policies and estimates, as well as error corrections. The document references relevant laws, regulations, and standards, and includes governance and disclosure protocols. It is not a financial report, earnings release, or announcement of voting results, nor is it a transcript or presentation. It is a governance-related document detailing internal rules and procedures for accounting changes and disclosures, which fits the category of Governance Information (CGR). The document length (5455 characters) and content confirm it is a substantive policy document, not a brief announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2025-04-24 Chinese
董事和高管人员持股及变动管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system regarding the holding and trading of company shares by directors and senior management of 海思科医药集团股份有限公司. It references relevant laws and regulations, outlines rules and restrictions on share transactions by directors and executives, and specifies reporting and disclosure obligations. There is no indication that this is an announcement of a report, a financial statement, or a regulatory filing. Instead, it is a governance document detailing internal rules and compliance related to directors' dealings and shareholding management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3271 characters, which is consistent with a detailed policy document rather than a brief announcement or certification.
2025-04-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.